Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride.

Arun T, Tomassini V, Sbardella E, de Ruiter MB, Matthews L, Leite MI, Gelineau-Morel R, Cavey A, Vergo S, Craner M, Fugger L, Rovira A, Jenkinson M, Palace J.

Brain. 2013 Jan;136(Pt 1):106-15. doi: 10.1093/brain/aws325.

PMID:
23365093
2.

Sodium channel blockers for neuroprotection in multiple sclerosis.

Yang C, Hao Z, Zhang L, Zeng L, Wen J.

Cochrane Database Syst Rev. 2015 Oct 21;(10):CD010422. doi: 10.1002/14651858.CD010422.pub2. Review.

PMID:
26486929
3.

The role of MRI in the evaluation of secondary progressive multiple sclerosis.

Brown JW, Chard DT.

Expert Rev Neurother. 2016;16(2):157-71. doi: 10.1586/14737175.2016.1134323. Epub 2016 Jan 22. Review. Erratum in: Expert Rev Neurother. 2016;16(4):463.

PMID:
26692498
4.

Translational strategies for neuroprotection in ischemic stroke--focusing on acid-sensing ion channel 1a.

O'Bryant Z, Vann KT, Xiong ZG.

Transl Stroke Res. 2014 Feb;5(1):59-68. doi: 10.1007/s12975-013-0319-5. Epub 2014 Jan 5. Review.

5.

Primary-progressive multiple sclerosis.

Miller DH, Leary SM.

Lancet Neurol. 2007 Oct;6(10):903-12. Review. Erratum in: Lancet Neurol. 2009 Aug;8(8):699.

PMID:
17884680
6.

Smooth muscle acid-sensing ion channel 1: pathophysiological implication in hypoxic pulmonary hypertension.

Jernigan NL.

Exp Physiol. 2015 Feb 1;100(2):111-20. doi: 10.1113/expphysiol.2014.081612. Epub 2015 Jan 14. Review.

7.

Disease-modifying treatments for progressive multiple sclerosis.

Comi G.

Mult Scler. 2013 Oct;19(11):1428-36. doi: 10.1177/1352458513502572. Review.

PMID:
24062415
8.

Neuroprotection in multiple sclerosis: therapeutic strategies and clinical trial design.

Kapoor R.

Curr Opin Neurol. 2006 Jun;19(3):255-9. Review.

PMID:
16702831
9.

Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids.

Pryce G, Riddall DR, Selwood DL, Giovannoni G, Baker D.

J Neuroimmune Pharmacol. 2015 Jun;10(2):281-92. doi: 10.1007/s11481-014-9575-8. Epub 2014 Dec 24. Review.

PMID:
25537576
10.

Magnetic resonance outcome measures in multiple sclerosis trials: time to rethink?

Filippi M, Preziosa P, Rocca MA.

Curr Opin Neurol. 2014 Jun;27(3):290-9. doi: 10.1097/WCO.0000000000000095. Review.

PMID:
24792339
11.

Neuronal injury in chronic CNS inflammation.

Zindler E, Zipp F.

Best Pract Res Clin Anaesthesiol. 2010 Dec;24(4):551-62. doi: 10.1016/j.bpa.2010.11.001. Epub 2010 Nov 29. Review.

PMID:
21619866
12.

Pathological mechanisms in progressive multiple sclerosis.

Mahad DH, Trapp BD, Lassmann H.

Lancet Neurol. 2015 Feb;14(2):183-93. doi: 10.1016/S1474-4422(14)70256-X. Review.

PMID:
25772897
13.

Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance.

Miller DH, Barkhof F, Frank JA, Parker GJ, Thompson AJ.

Brain. 2002 Aug;125(Pt 8):1676-95. Review.

PMID:
12135961
14.

Sodium channel blockers and neuroprotection in multiple sclerosis using lamotrigine.

Kapoor R.

J Neurol Sci. 2008 Nov 15;274(1-2):54-6. doi: 10.1016/j.jns.2008.03.019. Epub 2008 May 19. Review.

PMID:
18486153
15.

Neuroprotection in multiple sclerosis: a therapeutic approach.

Maghzi AH, Minagar A, Waubant E.

CNS Drugs. 2013 Oct;27(10):799-815. doi: 10.1007/s40263-013-0093-7. Review.

PMID:
23955320
16.

Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses.

Giovannoni G, Cutter G, Sormani MP, Belachew S, Hyde R, Koendgen H, Knappertz V, Tomic D, Leppert D, Herndon R, Wheeler-Kingshott CAM, Ciccarelli O, Selwood D, di Cantogno EV, Ben-Amor AF, Matthews P, Carassiti D, Baker D, Schmierer K.

Mult Scler Relat Disord. 2017 Feb;12:70-78. doi: 10.1016/j.msard.2017.01.007. Epub 2017 Jan 17. Review.

PMID:
28283111
17.

The Role of Advanced Magnetic Resonance Imaging Techniques in Multiple Sclerosis Clinical Trials.

Mahajan KR, Ontaneda D.

Neurotherapeutics. 2017 Oct;14(4):905-923. doi: 10.1007/s13311-017-0561-8. Review.

PMID:
28770481
18.

Assessing Repair in Multiple Sclerosis: Outcomes for Phase II Clinical Trials.

Sormani MP, Pardini M.

Neurotherapeutics. 2017 Oct;14(4):924-933. doi: 10.1007/s13311-017-0558-3. Review.

PMID:
28695472

Supplemental Content

Support Center